MBL Inks Pact with Envoy, Provides Access to RIP-Chip | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Medical & Biological Laboratories today announced it has signed a non-exclusive agreement with Envoy Therapeutics to provide it access to MBL's RIP-Chip technology.

Under the terms of the deal, MBL will receive an upfront payment of an undisclosed amount, annual licensing fees and potential milestone payments. Envoy will use the RIP-Chip for drug discovery and development.

Further terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.